Clodronic acid

Clodronic acid (INN) or clodronate disodium (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its potent anti-inflammatory and analgesic effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-α.[1]

Clodronic acid
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.031.090
Chemical and physical data
FormulaCH4Cl2O6P2
Molar mass244.88 g·mol−1
3D model (JSmol)
  (verify)

Use in human medicine

An Italian study compared the analgesic effect of clodronic acid versus acetaminophen in rheumatic condition related pain. Study result show a reduction in pain in favor of clodronic acid that provided more analgesia than 3 grams/day of acetaminophen. Clodronic acid is also used in experimental medicine to selectively deplete macrophages.

Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent. It is not approved for use in the United States, because it has too many adverse effects.

Use in equine medicine

Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of bone resorptive processes of navicular syndrome. It is given by intramuscular injection at one point in time, with the total dose divided into 2-3 sites on the horse. Clinical effects (e.g. improvement of lameness) after a single treatment can be seen up to 6 months post-treatment.

Adverse reactions and contraindications

Clodronic acid has been shown to have several adverse effects. These include:[2]

  • Signs of discomfort, agitation, or colic, usually within 2 hours of treatment.
  • Head shaking
  • Lip licking

Notes and references
  1. Pennanen, Niina; Lapinjoki, Seppo; Urtti, Arto; Mönkkönen, Jukka (1995). "Effect of Liposomal and Free Bisphosphonates on the IL-1β, IL-6 and TNFα Secretion from RAW 264 Cells in Vitro". Pharmaceutical Research. 12 (6): 916–922. doi:10.1023/A:1016281608773. ISSN 0724-8741.
  2. U.S. Food and Drug Administration. "FDA Provides Equine Veterinarians with Important Information about TILDREN and OSPHOS for Navicular Syndrome in Horses". Retrieved 3 January 2015.
gollark: That would be stupid.
gollark: RPis have onboard ethernet anyway, I don't understand your suggestion.
gollark: The ethernet shield thing? For wireless? What?
gollark: WiFi is "radio".
gollark: This probably could be done with a raspberry pi, one of the RPi camera modules, and some software.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.